These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 35001868)

  • 1. Functional CDKN2A assay identifies frequent deleterious alleles misclassified as variants of uncertain significance.
    Kimura H; Paranal RM; Nanda N; Wood LD; Eshleman JR; Hruban RH; Goggins MG; Klein AP; ; Roberts NJ
    Elife; 2022 Jan; 11():. PubMed ID: 35001868
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Role of Inherited Pathogenic CDKN2A Variants in Susceptibility to Pancreatic Cancer.
    Kimura H; Klein AP; Hruban RH; Roberts NJ
    Pancreas; 2021 Sep; 50(8):1123-1130. PubMed ID: 34714275
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gene-Level Associations in Patients With and Without Pathogenic Germline Variants in
    Astiazaran-Symonds E; Graham C; Kim J; Tucker MA; Ingvar C; Helgadottir H; Pastorino L; van Doorn R; Sampson JN; Zhu B; Bruno W; Queirolo P; Fornarini G; Sciallero S; Carter B; Hicks B; Hutchinson A; Jones K; Stewart DR; Chanock SJ; Freedman ND; Landi MT; Höiom V; Puig S; Gruis N; Yang XR; Ghiorzo P; Goldstein AM
    JCO Precis Oncol; 2022 Nov; 6():e2200145. PubMed ID: 36409970
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comprehensive analysis of candidate genes in familial pancreatic cancer families reveals a high frequency of potentially pathogenic germline variants.
    Earl J; Galindo-Pumariño C; Encinas J; Barreto E; Castillo ME; Pachón V; Ferreiro R; Rodríguez-Garrote M; González-Martínez S; Ramon Y Cajal T; Diaz LR; Chirivella-Gonzalez I; Rodriguez M; de Castro EM; García-Seisdedos D; Muñoz G; Rosa JMR; Marquez M; Malats N; Carrato A
    EBioMedicine; 2020 Mar; 53():102675. PubMed ID: 32113160
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk of Syndrome-Associated Cancers Among First-Degree Relatives of Patients With Pancreatic Ductal Adenocarcinoma With Pathogenic or Likely Pathogenic Germline Variants.
    Chen X; Meyer MA; Kemppainen JL; Horibe M; Chandra S; Majumder S; Petersen GM; Rabe KG
    JAMA Oncol; 2023 Jul; 9(7):955-961. PubMed ID: 37200008
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Germline sequence analysis of RABL3 in a large series of pancreatic ductal adenocarcinoma patients reveals no evidence of deleterious variants.
    Roberts NJ; Grant RC; Gallinger S; Klein AP;
    Genes Chromosomes Cancer; 2021 Aug; 60(8):559-564. PubMed ID: 33724601
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genotype-phenotype correlations for pancreatic cancer risk in Dutch melanoma families with pathogenic
    Overbeek KA; Rodríguez-Girondo MD; Wagner A; van der Stoep N; van den Akker PC; Oosterwijk JC; van Os TA; van der Kolk LE; Vasen HFA; Hes FJ; Cahen DL; Bruno MJ; Potjer TP
    J Med Genet; 2021 Apr; 58(4):264-269. PubMed ID: 32482799
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pancreatic Cancer Surveillance in Carriers of a Germline
    Klatte DCF; Boekestijn B; Wasser MNJM; Feshtali Shahbazi S; Ibrahim IS; Mieog JSD; Luelmo SAC; Morreau H; Potjer TP; Inderson A; Boonstra JJ; Dekker FW; Vasen HFA; van Hooft JE; Bonsing BA; van Leerdam ME
    J Clin Oncol; 2022 Oct; 40(28):3267-3277. PubMed ID: 35658523
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A systematic review of the prevalence of germline pathogenic variants in patients with pancreatic cancer.
    Astiazaran-Symonds E; Goldstein AM
    J Gastroenterol; 2021 Aug; 56(8):713-721. PubMed ID: 34255164
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Functional single nucleotide polymorphisms within the cyclin-dependent kinase inhibitor 2A/2B region affect pancreatic cancer risk.
    Campa D; Pastore M; Gentiluomo M; Talar-Wojnarowska R; Kupcinskas J; Malecka-Panas E; Neoptolemos JP; Niesen W; Vodicka P; Delle Fave G; Bueno-de-Mesquita HB; Gazouli M; Pacetti P; Di Leo M; Ito H; Klüter H; Soucek P; Corbo V; Yamao K; Hosono S; Kaaks R; Vashist Y; Gioffreda D; Strobel O; Shimizu Y; Dijk F; Andriulli A; Ivanauskas A; Bugert P; Tavano F; Vodickova L; Zambon CF; Lovecek M; Landi S; Key TJ; Boggi U; Pezzilli R; Jamroziak K; Mohelnikova-Duchonova B; Mambrini A; Bambi F; Busch O; Pazienza V; Valente R; Theodoropoulos GE; Hackert T; Capurso G; Cavestro GM; Pasquali C; Basso D; Sperti C; Matsuo K; Büchler M; Khaw KT; Izbicki J; Costello E; Katzke V; Michalski C; Stepien A; Rizzato C; Canzian F
    Oncotarget; 2016 Aug; 7(35):57011-57020. PubMed ID: 27486979
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BRCA1, BRCA2, PALB2, and CDKN2A mutations in familial pancreatic cancer: a PACGENE study.
    Zhen DB; Rabe KG; Gallinger S; Syngal S; Schwartz AG; Goggins MG; Hruban RH; Cote ML; McWilliams RR; Roberts NJ; Cannon-Albright LA; Li D; Moyes K; Wenstrup RJ; Hartman AR; Seminara D; Klein AP; Petersen GM
    Genet Med; 2015 Jul; 17(7):569-77. PubMed ID: 25356972
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High Growth Rate of Pancreatic Ductal Adenocarcinoma in
    Ibrahim IS; Wasser MN; Wu Y; Inderson A; de Vos Tot Nederveen Cappel WH; Morreau H; Hes FJ; Veenendaal RA; Putter H; Feshtali S; van Mil AM; Gruis NA; Tollenaar RA; Bergman W; Bonsing BA; Vasen HFA
    Cancer Prev Res (Phila); 2018 Sep; 11(9):551-556. PubMed ID: 29991580
    [No Abstract]   [Full Text] [Related]  

  • 13. Multiple rare variants in high-risk pancreatic cancer-related genes may increase risk for pancreatic cancer in a subset of patients with and without germline CDKN2A mutations.
    Yang XR; Rotunno M; Xiao Y; Ingvar C; Helgadottir H; Pastorino L; van Doorn R; Bennett H; Graham C; Sampson JN; Malasky M; Vogt A; Zhu B; Bianchi-Scarra G; Bruno W; Queirolo P; Fornarini G; Hansson J; Tuominen R; Burdett L; Hicks B; Hutchinson A; Jones K; Yeager M; Chanock SJ; Landi MT; Höiom V; Olsson H; Gruis N; Ghiorzo P; Tucker MA; Goldstein AM
    Hum Genet; 2016 Nov; 135(11):1241-1249. PubMed ID: 27449771
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patients with both pancreatic adenocarcinoma and melanoma may harbor germline CDKN2A mutations.
    Lal G; Liu L; Hogg D; Lassam NJ; Redston MS; Gallinger S
    Genes Chromosomes Cancer; 2000 Apr; 27(4):358-61. PubMed ID: 10719365
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence of CDKN2A mutations in pancreatic cancer patients: implications for genetic counseling.
    McWilliams RR; Wieben ED; Rabe KG; Pedersen KS; Wu Y; Sicotte H; Petersen GM
    Eur J Hum Genet; 2011 Apr; 19(4):472-8. PubMed ID: 21150883
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk of multiple pancreatic cancers in CDKN2A-p16-Leiden mutation carriers.
    Ibrahim I; Sibinga Mulder BG; Bonsing B; Morreau H; Farina Sarasqueta A; Inderson A; Luelmo S; Feshtali S; Potjer TP; de Vos Tot Nederveen Cappel W; Wasser M; Vasen HFA
    Eur J Hum Genet; 2018 Aug; 26(8):1227-1229. PubMed ID: 29769629
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of Germline Variants in Human DNA Damage Repair Genes and Response to Adjuvant Chemotherapy in Resected Pancreatic Ductal Adenocarcinoma.
    Hu H; Zhu Y; Pu N; Burkhart RA; Burns W; Laheru D; Zheng L; He J; Goggins MG; Yu J
    J Am Coll Surg; 2020 Nov; 231(5):527-535.e14. PubMed ID: 32659497
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunohistochemically detected expression of 3 major genes (CDKN2A/p16, TP53, and SMAD4/DPC4) strongly predicts survival in patients with resectable pancreatic cancer.
    Oshima M; Okano K; Muraki S; Haba R; Maeba T; Suzuki Y; Yachida S
    Ann Surg; 2013 Aug; 258(2):336-46. PubMed ID: 23470568
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Germline variants in cancer-predisposing genes in pancreatic cancer patients with a family history of cancer.
    Terashima T; Morizane C; Ushiama M; Shiba S; Takahashi H; Ikeda M; Mizuno N; Tsuji K; Yasui K; Azemoto N; Satake H; Nomura S; Yachida S; Sugano K; Furuse J
    Jpn J Clin Oncol; 2022 Oct; 52(10):1105-1114. PubMed ID: 36135357
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Benefit of Surveillance for Pancreatic Cancer in High-Risk Individuals: Outcome of Long-Term Prospective Follow-Up Studies From Three European Expert Centers.
    Vasen H; Ibrahim I; Ponce CG; Slater EP; Matthäi E; Carrato A; Earl J; Robbers K; van Mil AM; Potjer T; Bonsing BA; de Vos Tot Nederveen Cappel WH; Bergman W; Wasser M; Morreau H; Klöppel G; Schicker C; Steinkamp M; Figiel J; Esposito I; Mocci E; Vazquez-Sequeiros E; Sanjuanbenito A; Muñoz-Beltran M; Montans J; Langer P; Fendrich V; Bartsch DK
    J Clin Oncol; 2016 Jun; 34(17):2010-9. PubMed ID: 27114589
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.